Presentation Information

[O8-02]Antibody-Dependent Enhancement in Dengue Vaccine Evaluations: Key Insights

*Kouichi Morita1,2, Dengue Vaccine Development Group2 (1. Nagasaki University, Dejima Infectious Disease Research Alliance (DIDA) (Japan), 2. Nagasaki University, Vaccine Research and Development Center (VRDC) (Japan))

Login required to view

Login is required to view some content.

Comment

To browse or post comments, you must log in.Log in